Authors

• D. Ioannides (ORCID: https://orcid.org/0000-0002-8997-9889)
• Maryam Shayesteh Alam
• John R Ingram (ORCID: https://orcid.org/0000-0002-5257-1142)
• Łukasz Matusiak (ORCID: https://orcid.org/0000-0003-2067-4929)
• Ivette Alarcón (ORCID: https://orcid.org/0000-0002-6738-2651)
• Angela Llobet Martinez
• Alexa B. Kimball (ORCID: https://orcid.org/0000-0001-9405-0479)
• Jacek Cezary Szepietowski (ORCID: https://orcid.org/0000-0003-0766-6342)
• Magdalena B. Wozniak (ORCID: https://orcid.org/0000-0002-4411-2747)
• N. Thomas (ORCID: https://orcid.org/0000-0002-0146-0071)
• Christelle C Pieterse
• Christine-Elke Ortmann
• Georgios Kokolakis
• Shoba Ravichandran

Institutions

• Wrocław University of Science and Technology (PL)
• Novartis (Switzerland) (CH)
• Beth Israel Deaconess Medical Center (US)
• Harvard University (US)
• Aristotle University of Thessaloniki (GR)
• Wroclaw Medical University (PL)
• Humboldt-Universität zu Berlin (DE)
• Barrie Urology Group (CA)
• Novartis (United States) (US)
• Novartis (Ireland) (IE)
• AGH University of Krakow (PL)
• Cardiff University (GB)

Publication Details

Journal

Dermatology and Therapy

Published

2025-05-15

DOI

https://doi.org/10.1007/s13555-025-01426-x

Citations

1

Primary Topic

Hidradenitis Suppurativa and Treatments

Type

article

Field-Weighted Citation Impact

2.00

Funders

• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• Novartis
• Sanofi
• Beth Israel Deaconess Medical Center
• Incyte
• Novartis Pharma